In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections

Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1 and -2). Seven hundred ninety baseline isolates, including , β-hemoly...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2019-04, Vol.63 (4)
Main Authors: Noviello, Stephanie, Magnet, Sophie, Hawser, Stephen, Huang, David B
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
Double-Blind Method
Humans
Methicillin - pharmacology
Methicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus - drug effects
Microbial Sensitivity Tests
Pyrimidines
Pyrimidines - pharmacology
Skin - microbiology
Skin Diseases, Bacterial
Skin Diseases, Bacterial - drug therapy
Skin Diseases, Bacterial - microbiology
Staphylococcal Infections
Staphylococcal Infections - drug therapy
Staphylococcal Infections - microbiology
Staphylococcus aureus
Staphylococcus aureus - drug effects
Susceptibility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1 and -2). Seven hundred ninety baseline isolates, including , β-hemolytic streptococci, and group, underwent antibacterial susceptibility testing. Iclaprim had an MIC of 0.12 μg/ml for (0.12 μg/ml for methicillin susceptible, 0.25 μg/ml for methicillin resistant), 0.25 μg/ml for β-hemolytic streptococci, and 0.008 μg/ml for group. Iclaprim demonstrated potent activity against these Gram-positive ABSSSI isolates.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02239-18